Aim The aim of this study was to examine the pharmacokinetics of donepezil HCl and ketoconazole separately, and in combination, following administration of single and multiple oral doses. Methods This was an open-label, randomized, three-period crossover study in healthy volunteers (n=21). During each treatment period, subjects received single daily doses of either donepezil HCl (5 mg ), ketoconazole (200 mg), or a combination of both drugs for 7 consecutive days. Pharmacokinetic comparisons were made between treatment groups for the day 1 and day 7 profiles. Each treatment period was followed by a 3-week, drug-free washout period. Results On both day 1 and day 7, a statistically significant difference was observed between the donepezil and the donepezil+ketoconazole treatment groups in terms of C max and AUC (0-24) of donepezil. The concurrent administration of both drugs resulted in a 12% greater C max (9.5 ng ml −1 versus 8.4 ng ml −1 ; P=0.01) and a 12% greater AUC (0-24) (135.2 ng h ml −1 versus 118.7 ng h ml −1 ; P=0.001) than donepezil alone on day 1, and a 26.8% greater C max (37.7 ng ml −1 versus 27.6 ng ml −1 ; P<0.0001) and a 26.4% greater AUC (0-24) (680.9 ng h ml −1 versus 501.0 ng h ml −1 ; P<0.0001) than donepezil alone on day 7.
Introduction found to have a greater specificity for AChE as opposed to Cholinergic deficit is one of the major pathological features butyrylcholinesterase (BuChE) than either physostigmine or of Alzheimer's disease. This deficit has been associated with tacrine, and a longer duration of action than either of these the loss of cognition and memory, the primary symptoms drugs [9] . In clinical trials, treatment with single daily doses of this disorder [1] . In an attempt to alleviate these clinical of either 5 or 10 mg of donepezil significantly improved symptoms, therapeutic investigations have focused on cognition and global function in patients with Alzheimer's enhancing the action of the remaining cholinergic neurones.
disease [10] [11] [12] . Treatment with donepezil was well tolerated To date, the most successful approach has been in the and was not associated with hepatotoxicity. Adverse events, development of cholinergic agents, in particular, acetylwhen present, tended to be mild and transient gastrointestinal cholinesterase (AChE) inhibitors [2, 3] . The first of the disturbances, such as abdominal pain, nausea and vomiting. 'new-generation' AChE inhibitors used in the sympAll of these events are consistent with an increase in tomatic treatment of mild-moderate Alzheimer's disease is cholinergic stimulation and resolved within a few days for donepezil HCl. most patients, without the need for dose modification [11] . Donepezil HCl (also known as E2020 or AriceptA, the In healthy individuals, the pharmacokinetics of donepezil registered trademark of Eisai Co. Ltd, Tokyo, Japan) is a are characterized by hepatic metabolism and slow plasma distinct, piperidine-based agent that inhibits the enzyme clearance (0. using once-daily dosing.
Ketoconazole is an imidazole derivative that is adminisleast 12 h prior to drug administration. Subjects were fasted overnight (8 h) prior to receiving their first dose of tered as a treatment for superficial and systemic fungal infections [14] . It is a specific, potent inhibitor of the medication on the morning of day 1. Following drug administration, blood samples for analytical determinations cytochrome P-450 isoenzyme CYP-3A4 via which numerous compounds are metabolized. It has been shown to were collected at specified intervals during the next 24 h. Subjects were discharged from the study site the following reduce the metabolism of other drugs sharing the CYP-3A4 pathway, including cyclosporin, warfarin, terfenadine, astemmorning, after providing a 24-h blood sample. The subjects returned to the clinic as out-patients for the izole and some benzodiazepines [15, 16] . In addition, drug interactions with ketoconazole have also been reported for next four mornings (48, 72, 96 and 120 h) to provide trough blood samples for pharmacokinetic analysis and to receive other medications, including corticosteroids, antihistamines and antacids [17] [18] [19] .
their daily dose of medication. They were re-admitted to the study site on the evening of day 6 and repeated the As donepezil is predominantly metabolized by CYP-3A4, and to a lesser extent by CYP-2D6 (AriceptA US package same schedule of events as on day 0. The subjects were discharged from the study site on the morning of day 8, insert, 1998), concurrent administration of ketoconazole might affect plasma concentrations of donepezil. Therefore, 24 h after receiving their final dose of medication. They returned to the clinic as out-patients for the next six the primary objective of this study was to examine the pharmacokinetics of donepezil and ketoconazole adminismornings to provide blood for post-dose pharmacokinetic analyses (to 168 h). During the course of the treatment tered separately and in combination, following single and multiple oral doses.
period, subjects were not allowed to consume caffeinecontaining food or drinks, and physical exercise was limited to normal walking.
Methods

Sample collection and analysis Subjects
Entry into the study was confined to healthy, non-smoking Venous blood samples for the determination of donepezil and/or ketoconazole concentrations in plasma were collected volunteers between 18 and 45 years of age who were within 20% of ideal body weight based on the Metropolitan 1 h prior to drug administration, and at 0. Tables (1983) . Subjects with evidence of clinically significant hepatic, and 7. Additional samples were taken at 144 and 168 h after the last dose of medication on day 7 of each treatment period. gastrointestinal, renal, respiratory, endocrine, haematological, neurological, psychiatric or cardiovascular system abnormaliImmediately after collection, the blood samples were placed on ice and centrifuged for 15 min (2000 g at 4°C). ties were specifically excluded from the study, as were those who had a known or suspected history of alcohol or drug Plasma was then removed and transferred into polypropylene tubes, which were stored upright at −20°C until analysis. misuse or a positive urine drug screen. None of the subjects had donated blood or had received investigational or Plasma concentrations of donepezil (hydrochloride salt) were determined using a specific high-performance liquid chroprescription medications within 1 month of commencing trial medication. matography (HPLC) method with UV detection [20] . Ketoconazole was also analysed using a standard HPLC The study was conducted in accordance with the principles stated in the Declaration of Helsinki, and the method with UV detection. The limits of detection for these assays were 2 ng ml −1 for donepezil and 0.04 mg ml
Institutional Review Board for Investigations Involving Human Subjects, Harris Laboratories, Lincoln, Nebraska, for ketoconazole. USA, approved the protocol. All subjects gave written informed consent prior to participation in the study.
Pharmacokinetic assessments
Characterization of donepezil and/or ketoconazole pharmProtocol acokinetics for each treatment phase was performed by analysing blood samples collected over a 24-h period This was an open-label, randomized, multiple-dose, threeperiod crossover study. The three randomized treatments following initial dose administration, and a 168-h period following final dose administration. administered in this study were (1) donepezil HCl, 5 mg tablet, (2) ketoconazole, 200 mg tablet (NizoralA, Janssen), Pharmacokinetic parameters for both drugs were estimated by a non-compartmental method. Peak plasma concentration and (3) donepezil, 5 mg+ketoconazole, 200 mg. Each treatment period was 7 days in duration and was followed (C max ) and the time at which it occurred (t max ) were recorded from the observed values. The terminal disposition by a 3-week, drug-free washout period. The dose of donepezil was chosen on the basis of results of clinical phases of both donepezil and ketoconazole were identified by visual inspection of each subject's log concentrationefficacy studies conducted in the USA, and the dose of ketoconazole is the recommended therapeutic dose for time curve. The terminal disposition rate constant (l z ) was estimated as −2.303 multiplied by the slope of the best-fit treatment provided by the Physicians' Desk Reference.
All volunteers were screened by medical history, ECG linear regression line of the terminal phase. The terminal half-life (t D ) was calculated as 0.693/l z , and the area under and laboratory and physical examinations ≤2 weeks prior to the start of the study. For each treatment period, subjects the plasma concentration-time curve from 0 to 24 h (AUC (0-24) ) was estimated using the trapezoidal rule. The were admitted to the study site on the evening of day 0, at Table 2 , the was Asian.
donepezil+ketoconazole group had a 26.8% greater C max (37.7 ng ml −1 versus 27.6 ng ml −1 ) and a 26.5% greater
Pharmacokinetics of donepezil AUC (0-24) (680.9 ng h ml −1 versus 501.1 ng h ml −1 ) than the donepezil-only group. There was also a significant Mean plasma donepezil concentrations were calculated for ( P<0.0001) increase of 16% in the rate of donepezil each time-point for both donepezil treatment groups accumulation (R A ) for the combination group, compared (donepezil alone, donepezil+ketoconazole). A plasma conwith the donepezil-only group (Table 2) , although this centration-time plot of these data is presented in Figure 1 .
increase is not considered to be clinically relevant. No On day 1, a statistically significant difference was observed significant differences in t max and t D were observed between between the donepezil and the donepezil+ketoconazole the two treatment groups. No significant sequence effects treatment groups in terms of C max ( P=0.01) and AUC were observed. of donepezil ( P=0.001). The combination group had a 12% greater C max (9.5 ng ml −1 versus 8.4 ng ml −1 ) and Steady-state pharmacokinetics a 12% greater AUC (0-24) (135.2 ng h ml −1 versus 118.7 ng h ml −1 ) compared with the donepezil-only group As this study involved only 7 consecutive days of drug (Table 1) . No significant difference in t max was observed administration during each treatment period and donepezil between the groups. No significant sequence effects were steady-state concentrations are not attained until 14-21 observed.
days, the effect of concomitant administration at steady state On day 7, a statistically significant difference was again was estimated using pharmacokinetic modelling. Projected steady-state plasma concentrations of donepezil during concomitant administration with ketoconazole were calculated by fitting day 1 and day 7 data to both a onecompartment model and a sigmoidal E max model. The mean trough concentration of donepezil at steady state was estimated to be 30.7 ng ml −1 and 27.7 ng ml −1 for the two models, respectively. Previous phase I studies with donepezil have calculated C min to be 21.4 ng ml −1 [21] . Using the one-compartment model, these data suggest that the concurrent administration of ketoconazole will produce a 30% increase in donepezil concentrations at steady state.
Using the E max model, a 23% increase in donepezil concentrations at steady state is predicted. per time-point for each ketoconazole treatment group in combination were similar to those for donepezil administered alone.
Discussion
Ketoconazole is a potent inhibitor of the P-450 isoenzyme CYP-3A4. Several reports have demonstrated that concurrent administration of this drug can reduce the metabolism of other drugs [15] [16] [17] [18] [19] . As CYP-3A4 is the primary route of donepezil metabolism, it is important to investigate whether co-administration with ketoconazole would produce any changes in donepezil metabolism and/or plasma concentrations. AUC (0-24) on both day 1 and day 7. There was no difference in the t max values of the two groups on either day 1 or 7 (ketoconazole alone, donepezil+ketoconazole). A plasma and no difference in t D on day 7. The rate of donepezil concentration-time plot of this mean data is presented accumulation in plasma (as reflected by the accumulation in Figure 2 .
ratio, R A ) was 16% higher for the donepezil+ketoconazole Results of the ketoconazole pharmacokinetic analyses group after 7 days of drug treatment. Clinical studies have are summarized in Tables 3 and 4 . On days 1 and 7, no
shown that donepezil accumulation continues until steady statistically significant differences in ketoconazole pharmacostate is achieved within 14-21 days [10]. As each treatment kinetics were observed when ketoconazole administered lasted for 7 days, steady-state donepezil plasma concentrations alone was compared with ketoconazole administered in during concurrent administration of both drugs were combination with donepezil. No significant sequence effects estimated using both a sigmoidal E max model and a onewere observed. compartment model. Donepezil concentrations were projected to increase by 23% in the E max model and by 30% in the one-compartment model.
Safety
Although both the observed and estimated increases in All treatments were well tolerated and no serious or donepezil concentrations were significant, they are smaller unexpected adverse events occurred during the course of than those produced by ketoconazole administered concomithe study. Treatment-emergent signs and symptoms were tantly with other agents sharing the CYP-3A4 pathway. mild or moderate in severity, and the incidence and severity This is most probably the result of donepezil also being of symptoms for donepezil and ketoconazole administered metabolized by CYP-2D6, as well as its slow rate of clearance from plasma. isoenzymes 1A2, 2C9, 2C19, 2D6 and 3A4 were all greater than 100 mm. In addition, the mean k i values for CYP-3A4 and CYP-2D6 were found to be 131 mm and 47 mm, events. Moreover, both the observed and the estimated
